New Pentasaccharides for Prophylaxis of Deep Vein Thrombosis: Pharmacology

Chest

Volumn 124, Issue 6 SUPPL., 2003, Pages 364S-370S

  Bauer, Kenneth A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Fondaparinux; Idraparinux; Low molecular weight heparin; Pentasaccharide; Pharmacokinetics; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THROMBIN;

ARTERY THROMBOSIS; BLEEDING; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; ORTHOPEDIC SURGERY; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; SERUM; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT INDICATION; URINARY EXCRETION;

EID: 0346363869     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119(suppl 1):132S-175S
2. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993; 32:1671-1690
3. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991; 350(suppl):30-33
4. Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344:619-625
5. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305-1310
6. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298-1304
7. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715-1720
8. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726
9. Eriksson BI. A multicenter, randomized, placebo-controlled, double-blind study of fondaparinux for the prolonged prevention of venous thromboembolism in hip fracture surgery [abstract]. Presented at XXIIth World Congress of the Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT), San Diego CA, August 23-30, 2002, Abstract 430E, 337
10. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa-inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J 2001; 22:1716-1724
11. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81:214-220
12. Simmoons M. Oral presentation on the PENTUA clinical trial. Presented at 74th Annual Scientific Sessions of the American Heart Association, Anaheim CA, November 14, 2001
13. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000; 102:2726-2731
14. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363-10370
15. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5:141-148
16. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74:90-93
17. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248:6490-6505
18. Jin L, Abrahams JP, Skinner R, et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A 1997; 94:14683-14688
19. Olson ST, Björk I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267:12528-12538
20. Danielsson Å, Raub E, Lindahl U, et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261:15467-15473
21. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(suppl 1):64S-94S
22. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205
23. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701. Circ Res 1996; 76:590-600
24. Hérault JP, Donat F, Barzu T, et al. Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species: extrapolation to humans. Blood Coagul Fibrinolysis 1997; 8:161-167
25. Petitou M, Hérault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398:417-422
26. Hérault JP, Bernat A, Gaich C, et al. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Thromb Haemost 2002; 87:238-244
27. Hérault JP, Bernat A, Roye F, et al. Pharmacokinetics of new synthetic heparin mimetics. Thromb Haemost 2002; 87:985-989
28. Hérault JP, Gaich C, Bono F, et al. The structure of synthetic oligosaccharides in relation to factor IXa inhibition. Thromb Haemost 2002; 88:432-435
29. Petitou M, Duchaussoy P, Lederman I, et al. Synthesis of heparin fragments: a methyl-α pentaoside with high affinity for antithrombin III. Carbohydr Res 1987; 167:67-75
30. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15:1-26
31. Paolucci F, Clavies M, Donat F, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41(suppl):11-18
32. Walenga JM, Hoppensteadt D, Mayuga M, et al. Functionality of pentasaccharide depends on endogenous antithrombin levels [abstract]. Blood 2000; 96:817a
33. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74:1468-1473
34. Wessler S, Yin ET. On the antithrombotic action of heparin. Thromb Diath Haemorrh 1974; 32:71-78
35. Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide. Thromb Res 1997; 86:1-36
36. Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61:397-401
37. Lormeau JC, Hérault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic AT-III-binding pentasaccharide. Thromb Haemost 1993; 69:152-156
38. Lormeau JC, Hérault JP. The effect of the synthetic pentasaccharide SR90107/ORG31540 on thrombin generation ex vivo is uniquely due to AT-mediated neutralization of factor Xa. Thromb Haemost 1995; 74:1474-1477
39. Hérault JP, Bernat A, Pflieger AM, et al. Comparative effect of two direct and indirect inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283:16-22
40. Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of 25 patients with heparin associated thrombocytopenia. Thromb Haemost 1995; 74:1384-1385
41. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999; 5:259-266
42. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8:114-117
43. Bijsterveld NR, Moons AHM, Boekholdt SM, et al. Neutralization of the anticoagulant effect of fondaparinux (Arixtra) by recombinant activated factor VII in healthy male volunteers [abstract]. Hematol J 2002; 3(suppl 1):365
44. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41(suppl):1-9
45. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra®) in the dually perfused cotyledon in vitro. Thromb Haemost 2002; 87:831-835
46. Faaij RA, Burggraaf J, Schoemaker RC, et al. The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin. Clin Pharmacokinet 2002; 41(suppl):27-29
47. Ollier C, Santoni A, Faaij RA, et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002; 41(suppl):31-37
48. Mant T, Fournié P, Ollier C, et al. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41(suppl):39-45
49. Lieu C, Shi J, Donat F, et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41(suppl):19-26